Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,841 across all filing types
Latest filing 2024-10-31 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 普洛药业股份有限公司 regarding the progress of guarantees provided to its subsidiaries. It details specific guarantee contracts signed with banks, amounts, terms, and the financial status of the subsidiaries involved. The document includes information about the board's approval and cumulative guarantee amounts. There is no indication that this is a full financial report, audit report, or earnings release. It is a regulatory announcement about financing guarantees and related risk disclosures. The document length is 4363 characters, which is relatively short but contains substantive information about guarantees rather than just announcing a report publication. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company.
2024-10-31 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "普洛药业股份有限公司2024 年第三季度报告" which translates to "Puluo Pharmaceutical Co., Ltd. 2024 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the third quarter of 2024. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. The length of the document (12,465 characters) and the detailed financial content confirm it is the actual report, not just an announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-10-17 Chinese
关于盐酸金刚烷胺片获得美国FDA上市批准的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company about the FDA approval of a pharmaceutical product (Amantadine Hydrochloride Tablets). It includes details about the drug, its approval, market impact, and risk warnings. The document is short (1187 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is a regulatory announcement about a significant corporate event related to product approval, not a financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-10-08 Chinese
关于对下属公司担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the progress of guarantees provided by the company for its subsidiaries. It includes specific contract details, guarantee amounts, terms, and the board's opinion on the guarantees. The document is not a financial report, audit, or earnings release, nor is it a regulatory filing or certification. It is a formal announcement about the company's financing-related guarantees and obligations. This fits best under the category of Capital/Financing Update (CAP), as it relates to the company's financing activities and guarantees provided to support subsidiary loans.
2024-10-07 Chinese
关于回购股份期限届满暨回购实施结果的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement regarding the completion of a share repurchase program by 普洛药业股份有限公司. It details the repurchase plan, implementation period, number of shares repurchased, prices, compliance with regulations, and the impact on the company's share structure. It does not contain financial statements or earnings data but focuses on the company's buyback activity and related disclosures. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's repurchase of its own shares.
2024-09-27 Chinese
关于签署战略合作框架协议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the signing of a strategic cooperation framework agreement between the company and another party. It details the nature of the agreement, the parties involved, the scope of cooperation, and the expected impact on the company. There are no financial statements, no detailed financial performance data, nor is this a transcript or presentation. The document is a formal announcement of a corporate event (signing of a strategic cooperation agreement) rather than a report or detailed financial disclosure. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or M&A filings. It is not a regulatory certification or voting result. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a corporate event that does not fit other specific categories.
2024-09-26 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.